# Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1

> **NCT02323529** · PHASE3 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 18 (actual)

## Conditions studied

- Hereditary Tyrosinemia, Type I

## Interventions

- **DRUG:** Nitisinone

## Key facts

- **NCT ID:** NCT02323529
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323529, "Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02323529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*